Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy
Abstract Platinum-based neoadjuvant chemotherapy prior to radical cystectomy is the preferred treatment for muscle-invasive bladder cancer despite modest survival benefit and significant associated toxicities. Here, we profile the global proteome of muscle-invasive bladder cancers pre- and post-neoa...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-024-55665-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571522986803200 |
|---|---|
| author | A. Contreras-Sanz G. L. Negri M. J. Reike H. Z. Oo J. M. Scurll S. E. Spencer K. Nielsen K. Ikeda G. Wang C. L. Jackson S. Gupta M. E. Roberts D. M. Berman R. Seiler G. B. Morin P. C. Black |
| author_facet | A. Contreras-Sanz G. L. Negri M. J. Reike H. Z. Oo J. M. Scurll S. E. Spencer K. Nielsen K. Ikeda G. Wang C. L. Jackson S. Gupta M. E. Roberts D. M. Berman R. Seiler G. B. Morin P. C. Black |
| author_sort | A. Contreras-Sanz |
| collection | DOAJ |
| description | Abstract Platinum-based neoadjuvant chemotherapy prior to radical cystectomy is the preferred treatment for muscle-invasive bladder cancer despite modest survival benefit and significant associated toxicities. Here, we profile the global proteome of muscle-invasive bladder cancers pre- and post-neoadjuvant chemotherapy treatment using archival formalin-fixed paraffin-embedded tissue. We identify four pre-neoadjuvant chemotherapy proteomic clusters with distinct biology and response to therapy and integrate these with transcriptomic subtypes and immunohistochemistry. We observe proteomic plasticity post-neoadjuvant chemotherapy that is associated with increased extracellular matrix and reduced keratinisation compared to pre-neoadjuvant chemotherapy. Post-neoadjuvant chemotherapy clusters appear to be differentially enriched for druggable proteins. For example, MTOR and PARP are over-expressed at the protein level in tumours identified as neuronal-like. In addition, we determine that high intra-tumoural proteome heterogeneity in pre-neoadjuvant chemotherapy tissue is associated with worse prognosis. Our work highlights aspects of muscle-invasive bladder cancer biology associated with clinical outcomes and suggests biomarkers and therapeutic targets based on proteomic clusters. |
| format | Article |
| id | doaj-art-76505e2c7dd94cb0a24de689ef09d43b |
| institution | Kabale University |
| issn | 2041-1723 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj-art-76505e2c7dd94cb0a24de689ef09d43b2025-02-02T12:31:31ZengNature PortfolioNature Communications2041-17232025-02-0116111810.1038/s41467-024-55665-1Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapyA. Contreras-Sanz0G. L. Negri1M. J. Reike2H. Z. Oo3J. M. Scurll4S. E. Spencer5K. Nielsen6K. Ikeda7G. Wang8C. L. Jackson9S. Gupta10M. E. Roberts11D. M. Berman12R. Seiler13G. B. Morin14P. C. Black15Department of Urologic Sciences, University of British ColumbiaCanada’s Michael Smith Genome Sciences Centre, BC Cancer Research Institute, University of British ColumbiaDepartment of Urologic Sciences, University of British ColumbiaDepartment of Urologic Sciences, University of British ColumbiaDepartment of Urologic Sciences, University of British ColumbiaCanada’s Michael Smith Genome Sciences Centre, BC Cancer Research Institute, University of British ColumbiaCanada’s Michael Smith Genome Sciences Centre, BC Cancer Research Institute, University of British ColumbiaDepartment of Urologic Sciences, University of British ColumbiaDepartment of Pathology and Laboratory Medicine, University of British ColumbiaDepartment of Pathology and Molecular Medicine, Queen’s UniversityDepartment of Oncology, The Cleveland ClinicDepartment of Urologic Sciences, University of British ColumbiaDepartment of Pathology and Molecular Medicine, Queen’s UniversityDepartment of Urologic Sciences, University of British ColumbiaCanada’s Michael Smith Genome Sciences Centre, BC Cancer Research Institute, University of British ColumbiaDepartment of Urologic Sciences, University of British ColumbiaAbstract Platinum-based neoadjuvant chemotherapy prior to radical cystectomy is the preferred treatment for muscle-invasive bladder cancer despite modest survival benefit and significant associated toxicities. Here, we profile the global proteome of muscle-invasive bladder cancers pre- and post-neoadjuvant chemotherapy treatment using archival formalin-fixed paraffin-embedded tissue. We identify four pre-neoadjuvant chemotherapy proteomic clusters with distinct biology and response to therapy and integrate these with transcriptomic subtypes and immunohistochemistry. We observe proteomic plasticity post-neoadjuvant chemotherapy that is associated with increased extracellular matrix and reduced keratinisation compared to pre-neoadjuvant chemotherapy. Post-neoadjuvant chemotherapy clusters appear to be differentially enriched for druggable proteins. For example, MTOR and PARP are over-expressed at the protein level in tumours identified as neuronal-like. In addition, we determine that high intra-tumoural proteome heterogeneity in pre-neoadjuvant chemotherapy tissue is associated with worse prognosis. Our work highlights aspects of muscle-invasive bladder cancer biology associated with clinical outcomes and suggests biomarkers and therapeutic targets based on proteomic clusters.https://doi.org/10.1038/s41467-024-55665-1 |
| spellingShingle | A. Contreras-Sanz G. L. Negri M. J. Reike H. Z. Oo J. M. Scurll S. E. Spencer K. Nielsen K. Ikeda G. Wang C. L. Jackson S. Gupta M. E. Roberts D. M. Berman R. Seiler G. B. Morin P. C. Black Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy Nature Communications |
| title | Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy |
| title_full | Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy |
| title_fullStr | Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy |
| title_full_unstemmed | Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy |
| title_short | Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy |
| title_sort | proteomic profiling identifies muscle invasive bladder cancers with distinct biology and responses to platinum based chemotherapy |
| url | https://doi.org/10.1038/s41467-024-55665-1 |
| work_keys_str_mv | AT acontrerassanz proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy AT glnegri proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy AT mjreike proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy AT hzoo proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy AT jmscurll proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy AT sespencer proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy AT knielsen proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy AT kikeda proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy AT gwang proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy AT cljackson proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy AT sgupta proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy AT meroberts proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy AT dmberman proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy AT rseiler proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy AT gbmorin proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy AT pcblack proteomicprofilingidentifiesmuscleinvasivebladdercancerswithdistinctbiologyandresponsestoplatinumbasedchemotherapy |